The UCLA Clinical Genomics Center is delighted to extend our services and expertise to the Asian populations served by Rainbow Genomics
HONG KONG and SAN FRANCISCO (PRWEB) April 26, 2018
Hong Kong-based Rainbow Genomics announced the contracting of data analysis and clinical interpretation services with the UCLA Clinical Genomics Center. This process is coupled with Rainbow Genomics’ whole exome sequencing performed at its CAP-accredited laboratory. The fully-integrated capabilities deliver whole exome sequencing tests covering cardio, adult and pediatric genetic disorders. Clinical reports based on clear medical evidence will be issued by U.S. board-certified medical directors at the UCLA Clinical Genomics Center.
These tests are exome-sequencing-based, covering over 22,000 genes, which may increase diagnostic yields (identifying the cause of a disorder), and cover Asian-specific genes that may not be included in many microarray- or panel-based gene tests.
Limited by traditional testing of only tens or even hundreds of genes at a time, many patients with suspected genetic disorders have suffered for years without obtaining a diagnosis, a frustrating process often described as a “Diagnostic Odyssey”. Whole exome sequencing is increasingly adopted by clinicians in the U.S. to quickly obtain a diagnosis for these “unresolved” cases. With a diagnosis, physicians can predict the course of the disorder, provide a prognosis, and in certain cases, treat the disorder. The families, especially those with pediatric patients, can understand the genetic risks for other family members, and seek access to appropriate support networks.
UCLA Clinical Genomics Center is one of the first U.S. medical institutions offering clinical-grade whole exome sequencing for diagnosis of pediatric and adult genetic disorders. Leveraging their extensive expertise in diagnosis and treatment of hereditary diseases, Rainbow Genomics is committed to helping Asian patients by resolving their clinical cases. These undiagnosed cases, especially in the pediatric area, remain as a substantial medical burden for many local communities.
“The UCLA Clinical Genomics Center is delighted to extend our services and expertise to the Asian populations served by Rainbow Genomics," said Dr. Wayne Grody, Director of Molecular Diagnostics for the UCLA Health system. “While those countries have robust economies and impressive technology, they have remained underserved in the areas of genetic testing and genomic medicine. This collaboration will go a long way toward growing these services, with benefits on both sides of the Pacific."
“Rainbow Genomics is committed to bringing evidence-based genetic tests, supported by 'actionable' findings, to patients in Asia Pacific,” Said Daniel Siu, CEO of Rainbow Genomics. “Currently, obtaining a whole exome sequencing test from a leading U.S. medical institution without insurance coverage is prohibitively expensive. The relationship between UCLA Clinical Genomics Center and Rainbow Genomics enables many middle-class families to access exceptionally-high-quality exome sequencing genetic tests that may finally provide a diagnosis, something that these families have been seeking for years."
About Rainbow Genomics
Rainbow Genomics is committed to providing clinically-validated and affordable genetic tests to patients in Hong Kong, Japan, Singapore and other Asian countries. The company delivers clinical interpretations specifically for Asians, based on expert understanding of their genetics, and medical care experience in Hong Kong, Japan, and the United States. Rainbow Genomics specializes in providing whole exome sequencing and pharmacogenomic tests to enable physicians to use genomic information for diagnosis, treatment, and disease prevention. Visit us at rainbowgenomics.com.